Scott Ingrid U, Flynn Harry W, Dev Sundeep, Shaikh Saad, Mittra Robert A, Arevalo J Fernando, Kychenthal Andres, Acar Nur
Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Retina. 2008 Jan;28(1):138-42. doi: 10.1097/IAE.0b013e31815e9313.
To compare the rates of endophthalmitis after 20-gauge versus 25-gauge pars plana vitrectomy (PPV) and to investigate clinical features of, and visual acuity outcomes, for patients with endophthalmitis after PPV.
A computerized database search was performed at each author's institution to identify all patients who underwent PPV by any of the authors between January 1, 2005, and December 31, 2006, and were subsequently treated for endophthalmitis. In addition, all patients who underwent PPV and were subsequently treated for endophthalmitis at Pennsylvania State College of Medicine (Hershey, PA) and Bascom Palmer Eye Institute (Miami, FL) during the study period were included. The medical records of these patients were reviewed to confirm that the endophthalmitis was associated with PPV and to collect clinical data to meet the study objectives.
The incidence of endophthalmitis during the study period was 2 cases per 6,375 patients (or 1 case per 3,188 patients; 0.03%) for 20-gauge PPV compared with 11 cases per 1,307 patients (or 1 case per 119 patients; 0.84%) for 25-gauge PPV (P < 0.0001). Of 11 eyes that developed endophthalmitis after 25-gauge PPV, 9 received endophthalmitis prophylaxis with subconjunctival cefazolin after surgery. Median intraocular pressure on postoperative day 1 was 13 mmHg (range, 5-27 mmHg). Median time between PPV and endophthalmitis presentation was 3 days (range, 1-15 days). Presenting vision was hand motions or better in all eyes. Initial treatment included vitreous tap and injection of antibiotics in nine eyes and PPV and injection of antibiotics in two. All patients received intraocular treatment with vancomycin, and 10 received ceftazidime treatment. Eight patients had final visual acuity of >/=20/400, and four had visual acuity of >/=20/63. Cultures were negative in three cases; no culture specimens were obtained in one case. Six of the seven isolates were coagulase-negative staphylococci, and one was enterococcus. Five of six isolates tested for sensitivity to vancomycin were sensitive, and both isolates tested for sensitivity to ceftazidime were sensitive.
The rate of endophthalmitis after 25-gauge PPV was significantly higher than that after 20-gauge PPV. Endophthalmitis after 25-gauge PPV occurred within 15 days of PPV, was usually due to coagulase-negative staphylococci sensitive to vancomycin, and was associated with variable visual outcomes.
比较20G与25G经平坦部玻璃体切除术(PPV)后眼内炎的发生率,并调查PPV后发生眼内炎患者的临床特征及视力预后。
各作者所在机构通过计算机数据库检索,以识别2005年1月1日至2006年12月31日期间由任何一位作者实施PPV且随后接受眼内炎治疗的所有患者。此外,纳入研究期间在宾夕法尼亚州立医学院(宾夕法尼亚州好时)和巴斯科姆帕尔默眼科研究所(佛罗里达州迈阿密)接受PPV且随后接受眼内炎治疗的所有患者。对这些患者的病历进行审查,以确认眼内炎与PPV相关,并收集临床数据以满足研究目的。
研究期间,20G PPV的眼内炎发生率为每6375例患者2例(即每3188例患者1例;0.03%),而25G PPV为每1307例患者11例(即每119例患者1例;0.84%)(P<0.0001)。在25G PPV后发生眼内炎的11只眼中,9只在术后接受了结膜下头孢唑林预防眼内炎。术后第1天的眼压中位数为13 mmHg(范围5 - 27 mmHg)。PPV与眼内炎出现之间的时间中位数为3天(范围1 - 15天)。所有患眼的初始视力为手动或更好。初始治疗包括9只眼进行玻璃体穿刺并注射抗生素,2只眼进行PPV并注射抗生素。所有患者均接受了万古霉素眼内治疗,10例接受了头孢他啶治疗。8例患者的最终视力≥20/400,4例患者的视力≥20/63。3例培养结果为阴性;1例未获得培养标本。7株分离菌中有6株为凝固酶阴性葡萄球菌,1株为肠球菌。6株进行万古霉素敏感性测试的分离菌中有5株敏感,2株进行头孢他啶敏感性测试的分离菌均敏感。
25G PPV后眼内炎的发生率显著高于20G PPV后。25G PPV后眼内炎发生在PPV后15天内,通常由对万古霉素敏感的凝固酶阴性葡萄球菌引起,且与不同的视力预后相关。